Eli Lilly and Co Profit Margin
Data as of August 04, 2026
Profit Margin (TTM)
35.0%
Revenue (TTM)
$75.95B
Sector
Pharmaceuticals
Ticker
LLY
How It's Calculated
What This Means
Eli Lilly and Co's profit margin of 35.0% is strong, indicating the company retains a large share of revenue as net income.
About Eli Lilly and Co
Eli Lilly and Co (LLY) operates in the Pharmaceuticals sector, specifically in Pharmaceuticals. With a market capitalization of about $1.08T, it ranks as a mega-cap stock — one of the largest publicly traded companies.
Shares recently traded near $1121.36, within a 52-week range of $623.78 to $1249.45 (-10.3% from the high, +79.8% from the low). Beta of 0.51 indicates relatively lower volatility versus the market.
Trailing profit margin is about 35.0%, signaling a strong profit margin relative to many peers.
Understanding This Metric
Profit margin connects income-statement quality to valuation. For Eli Lilly and Co, trailing margin summarizes how much revenue converts to net profit after costs. In Pharmaceuticals, margins differ by business model — software and services often run higher margins than capital-intensive industries. Track margin trends across quarters; a stable or improving margin can support earnings durability, while sharp declines may warrant deeper review of guidance and competition.
Using This Number in Practice
At about 35.0% trailing profit margin, Eli Lilly and Co (LLY) suggests strong pricing power or cost discipline versus many large-cap peers. For large revenue bases, even a one-point margin move can shift earnings materially, so trend matters as much as the spot reading.
When comparing LLY to alternatives, combine margin with return on equity, revenue growth, and valuation. Use our margin calculator for scenario work, and browse the LLY metrics hub plus sector peers in the comparison section above.
Sector Comparison
Among Pharmaceuticals names on our S&P 100 coverage, Eli Lilly and Co's profit margin of 35.0% can be compared with peers such as JNJ (21.5%), MRK (13.6%), PFE (11.8%). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Pharmaceuticals stocks.
Key Takeaways
- LLY is grouped in the Pharmaceuticals sector for peer comparisons.
- Recent beta of 0.51 suggests lower-than-market price sensitivity.
- Trailing profit margin of 35.0% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for LLY.
Learn the full workflow
Compare PE with PB, PEG, EV/EBITDA, and market cap in one structured path.
Open the Stock Valuation hub →Other LLY Metrics
Frequently Asked Questions
What is LLY's profit margin?
Trailing profit margin measures net income as a percent of revenue. Eli Lilly and Co's margin is about 35.0% on this snapshot — higher margins often support stronger valuation multiples in Pharmaceuticals.
Is 35.0% strong for Pharmaceuticals?
Peers in Pharmaceuticals such as JNJ (21.5%), MRK (13.6%), BMY (12.3%) help benchmark LLY's 35.0%. Margins vary by sub-industry and accounting cycle.
How often is profit margin updated?
Margins update after quarterly earnings; price-only fields refresh on trading days. Data as of August 04, 2026.
Calculate the profit margin for any stock with our free calculator.
Open Margin Calculator →